Bridging Real-World Evidence Gaps

The Role of Literature-Derived RWE in Rare or Complex Indications

In this white paper, we reveal how literature-derived real-world evidence (RWE) can fill critical evidence gaps in rare and complex indications:

  • For NPM1-mutated AML, literature-derived RWE workflow surfaced >1,000 patients where an EHR dataset provided only a few dozen.
  • In PRKAG2 syndrome, it enabled detection of 2.7x more patients than prior reviews, with richer phenotyping and longitudinal follow-up.
  • In pediatric ABCC6 deficiency, it uncovered a heterogeneous, multi-organ phenotype in a previously uncharacterized subpopulation.

Complete the form to download the white paper.

The World’s Most Comprehensive Source of Genomic Evidence

Mastermind accelerates variant interpretation with immediate insight into the full text of millions of scientific articles. Prioritize your search results by clinical relevance and find what you are looking for 5-10 times faster

Explore Mastermind CORE
Every Missing Genetic Variant is a Patient Your Label Doesn't Reach
  • Rare disease and precision oncology programs rely on evidence fragmented across millions of published articles and supplemental datasets.
  • Genomenon builds the custom real-world evidence your program needs.
  • AI-powered search. Expert scientific curation.
  • The result: a broader label, more eligible patients, and a regulatory filing your team can defend.
Request a custom evidence build for your program
speak with an expert